177Lu-NY005

N/A

Report date: 2025/11/14 17:20:15

Base Information

Drug Name177Lu-NY005

Drug Alias NameLutetium-117-NY005177Lu-NY005

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionAnti-CLDN18Positron-emission tomography enhancers

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesWuxi Nuoyu Pharmaceutical Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesWuxi Nuoyu Pharmaceutical Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A